AIM ImmunoTech (AIM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$95,000.00

Revenue (quarter)

$26,000.00

Revenue growth (year over year)

+4.00%

Gross profit (trailing twelve months)

−$22,000.00

Gross margin

−23.16%

Net income (trailing twelve months)

−$14.3M

Net income (quarter)

−$3.8M

Net income growth (year over year)

−35.58%

Net margin

−15021.05%

Return on equity

−2382.30%

EPS (trailing twelve months)

−$0.70

Book value per share

$0.27

P/E (trailing twelve months)

—

Price to book

0.84

Debt to assets

39.17%

Payout ratio

—

Dividend yield

—

Company profile

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

• Is AIM ImmunoTech (AIM) profitable?

  No. AIM ImmunoTech reported a net loss of $14.3M over the trailing twelve months.

• How much revenue does AIM ImmunoTech (AIM) make?

  AIM ImmunoTech generated $95,000.00 in revenue over the trailing twelve months, up 4.00% year over year.

• How do I buy stock in AIM ImmunoTech (AIM)?

  AIM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.